Tilsotolimod with ipilimumab drives tumor responses in anti–pd-1 refractory melanoma

Cara Haymaker, Daniel H. Johnson, Ravi Murthy, Salah Eddine Bentebibel, Marc I. Uemura, Courtney W. Hudgens, Houssein Safa, Marihella James, Robert H.I. Andtbacka, Douglas B. Johnson, Montaser Shaheen, Michael A. Davies, Shah Rahimian, Srinivas K. Chunduru, Denái R. Milton, Michael T. Tetzlaff, Willem W. Overwijk, Patrick Hwu, Nashat Gabrail, Sudhir AgrawalGary Doolittle, Igor Puzanov, Joseph Markowitz, Chantale Bernatchez, Adi Diab

Producción científica: Articlerevisión exhaustiva

24 Citas (Scopus)

Huella

Profundice en los temas de investigación de 'Tilsotolimod with ipilimumab drives tumor responses in anti–pd-1 refractory melanoma'. En conjunto forman una huella única.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science